PhalconBio

The rise of antibiotic resistance presents a significant global health challenge, exacerbated by a 35-year stagnation in the development of new antibiotic classes. PhalconBio addresses this critical void by advancing next-generation antibacterial precision medicines derived from phage technology.

Bacteriophages, or phages, are naturally occurring viral predators that specifically infect and eliminate bacteria. This inherent specificity allows phage-based therapies to target pathogenic bacterial species precisely, thereby minimizing disruption to the patient's beneficial microbiome, a common drawback of broad-spectrum antibiotics.

PhalconBio's core innovation lies in its proprietary Engineered Phage Therapy (EPT) platform. This technology genetically enhances bacteriophages, integrating precision targeting capabilities with the phage-mediated delivery of antibacterial effector proteins. This approach transforms conventional phage therapy by significantly improving its efficacy and specificity.

The EPT platform facilitates a two-pronged attack on bacterial infections, designed to improve antibacterial efficacy, minimize the development of drug resistance, and enhance biofilm targeting. The outcome is the development of highly effective and safe new medicines, aiming to set a new standard in antibacterial treatment and offer a sustainable alternative to traditional antibiotics.

PhalconBio is positioned to address the urgent market need for novel antibacterial treatments. The development of these precision medicines aims to revolutionize patient care by providing effective solutions against drug-resistant infections, thereby contributing to global health security.

Keywords: Phage therapy, Antibiotic resistance, Antimicrobial drugs, Precision medicine, Bacteriophages, Engineered Phage Therapy (EPT), Drug development, Bacterial infections, Biofilm targeting, Microbiome